Security
Black Diamond Therapeutics, Inc. Common Stock · BDTX
BDTXNASDAQCommon stockCurrentCIK 1701541Updated Oct 6, 2026
Name history
Aset Therapeutics, Inc. · through Jan 4, 2018
BDTX price & chart
Loading TradingView…
NASDAQ:BDTX on TradingView ↗About the company
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.
In the news
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 157,733,000Source | 137,896,000Source | 125,029,000Source | 166,385,000Source | 149,986,000Source | 132,922,000Source | 176,245,000Source | 142,521,000Source | 143,010,000Source | 122,640,000Source | 158,567,000Source | 156,255,000Source |
| Property, Plant and Equipment, NetUSD | 1,128,000Source | 1,472,000Source | 310,000Source | 1,214,000Source | 1,558,000Source | 338,000Source | 1,300,000Source | 1,644,000Source | 365,000Source | 1,387,000Source | 1,730,000Source | 2,587,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,864,000Source | 23,425,000Source | 19,194,000Source | 29,993,000Source | 32,811,000Source | 30,071,000Source | 98,424,000Source | 25,422,000Source | 20,990,000Source | 36,437,000Source | 56,221,000Source | 34,315,000Source |
| Assets, CurrentUSD | 138,992,000Source | 115,538,000Source | 115,394,000Source | 146,726,000Source | 126,754,000Source | 122,967,000Source | 155,679,000Source | 118,806,000Source | 132,440,000Source | 101,176,000Source | 134,034,000Source | 127,706,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,489,000Source | 2,856,000Source | 4,888,000Source | 3,897,000Source | 3,783,000Source | 4,709,000Source | 3,279,000Source | 3,607,000Source | 3,788,000Source | 2,601,000Source | 2,634,000Source | 4,899,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,669,000Source | 19,767,000Source | 8,207,000Source | 17,460,000Source | 20,515,000Source | 8,757,000Source | 18,240,000Source | 21,252,000Source | 9,303,000Source | 19,009,000Source | 21,980,000Source | 24,794,000Source |
| Other Assets, NoncurrentUSD | 117,000Source | 293,000Source | 285,000Source | 161,000Source | 337,000Source | 29,000Source | 205,000Source | — | 73,000Source | 249,000Source | — | 0Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 31,581,000Source | 40,470,000Source | 28,938,000Source | 33,775,000Source | 38,965,000Source | 28,622,000Source | 34,729,000Source | 38,215,000Source | 30,799,000Source | 39,355,000Source | 41,831,000Source | 40,560,000Source |
| Commitments and ContingenciesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 8,000Source | 7,000Source | 8,000Source | 7,000Source | 7,000Source | 8,000Source | 7,000Source | 7,000Source | 8,000Source | 7,000Source | 7,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 575,626,000Source | 568,434,000Source | 579,832,000Source | 573,754,000Source | 566,694,000Source | 578,104,000Source | 572,093,000Source | 540,050,000Source | 576,842,000Source | 570,361,000Source | 534,187,000Source | 452,503,000Source |
| Retained Earnings (Accumulated Deficit)USD | -449,624,000Source | -471,122,000Source | -483,681,000Source | -441,126,000Source | -455,565,000Source | -473,776,000Source | -430,565,000Source | -435,656,000Source | -464,740,000Source | -487,107,000Source | -417,431,000Source | -334,989,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 142,000Source | 107,000Source | -68,000Source | -25,000Source | -115,000Source | -36,000Source | -19,000Source | -95,000Source | 101,000Source | 24,000Source | -27,000Source | -1,824,000Source |
| Stockholders' Equity Attributable to ParentUSD | 126,152,000Source | 97,426,000Source | 96,091,000Source | 132,610,000Source | 111,021,000Source | 104,300,000Source | 141,516,000Source | 104,306,000Source | 112,211,000Source | 83,285,000Source | 116,736,000Source | 115,695,000Source |
| Liabilities and EquityUSD | 157,733,000Source | 137,896,000Source | 125,029,000Source | 166,385,000Source | 149,986,000Source | 132,922,000Source | 176,245,000Source | 142,521,000Source | 143,010,000Source | 122,640,000Source | 158,567,000Source | 156,255,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,545,000Source | 20,800,000Source | 15,843,000Source | 16,805,000Source | 18,439,000Source | 14,534,000Source | 16,847,000Source | 16,854,000Source | 15,731,000Source | 20,573,000Source | 19,646,000Source | 15,261,000Source |
| Operating Lease, Liability, CurrentUSD | 3,634,000Source | 3,329,000Source | 3,875,000Source | 3,782,000Source | 3,256,000Source | 3,794,000Source | 3,705,000Source | 3,184,000Source | 3,713,000Source | 3,404,000Source | 3,113,000Source | 2,841,000Source |
| Accounts Payable, CurrentUSD | 975,000Source | 1,971,000Source | 1,404,000Source | 771,000Source | 763,000Source | 2,969,000Source | 2,628,000Source | 1,176,000Source | 579,000Source | 4,007,000Source | 2,324,000Source | 1,877,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,036,000Source | 19,670,000Source | 13,095,000Source | 16,970,000Source | 20,526,000Source | 14,088,000Source | 17,882,000Source | 21,361,000Source | 15,068,000Source | 18,782,000Source | 22,185,000Source | 25,299,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 14,570,000Source | 18,829,000Source | 14,439,000Source | 16,034,000Source | 17,676,000Source | 11,565,000Source | 14,219,000Source | 15,678,000Source | 15,152,000Source | 16,566,000Source | 17,322,000Source | 13,384,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,447,000Source | 1,700,000Source | 6,628,000Source | 10,627,000Source | 9,604,000Source | 12,197,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,232,000Source | 53,410,000Source | 29,614,000Source | -62,303,000Source | -66,717,000Source | -85,082,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 19,500,000Source | 8,547,000Source | -44,905,000Source | 16,968,000Source | 16,346,000Source | 53,366,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 33,000Source | 192,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -185,000Source | 32,000Source | -146,000Source | 25,547,000Source | 71,932,000Source | 177,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,083,000Source | 61,989,000Source | -15,437,000Source | -19,788,000Source | 21,561,000Source | -31,539,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 31,691,000Source | 24,251,000Source | 20,027,000Source | 30,817,000Source | 30,902,000Source | 99,245,000Source | 21,819,000Source | 37,256,000Source | 57,044,000Source | 35,483,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,739,000Source | 1,992,000Source | 1,511,000Source | 1,777,000Source | 1,447,000Source | 1,700,000Source | 6,628,000Source | 10,627,000Source | 9,604,000Source | 12,197,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| DepreciationUSD | — | — | — | — | 28,000Source | 86,000Source | 27,000Source | 87,000Source | 325,000Source | 343,000Source | 437,000Source | 508,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,232,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | 74,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,541,000Source | 5,216,000Source | 4,664,000Source | 4,101,000Source | 4,256,000Source | 4,964,000Source | 16,572,000Source | 27,469,000Source | 27,110,000Source | 28,391,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -2,250,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 226,000Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,498,000Source | -15,557,000Source | -9,905,000Source | -10,561,000Source | -9,036,000Source | 56,542,000Source | 22,367,000Source | -69,676,000Source | -82,442,000Source | -91,169,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,480,000Source | 2,573,000Source | 2,152,000Source | 2,859,000Source | 2,223,000Source | 2,012,000Source | 9,845,000Source | 9,105,000Source | 4,018,000Source | 3,909,000Source |
| Operating ExpensesUSD | — | — | 10,978,000Source | 18,130,000Source | 12,057,000Source | 13,420,000Source | 11,259,000Source | 15,470,000Source | 57,478,000Source | 78,781,000Source | 86,460,000Source | 92,828,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 5,279,000Source | 5,275,000Source | 5,218,000Source | 5,342,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,316,000Source | 2,057,000Source | 1,230,000Source | 1,741,000Source | 1,200,000Source | 1,417,000Source | 5,784,000Source | 6,923,000Source | 2,094,000Source | -354,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 0Source | 23,466,000Source | 164,026,000Source | 122,876,000Source | 61,887,000Source | 60,141,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 24,494,000Source | 71,850,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 177,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 70,000,000Source | 70,000,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -10,978,000Source | -18,130,000Source | -12,057,000Source | -13,420,000Source | -11,259,000Source | 54,530,000Source | 12,522,000Source | -78,781,000Source | -86,460,000Source | -92,828,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,316,000Source | 2,057,000Source | 1,230,000Source | 1,741,000Source | 1,200,000Source | 1,417,000Source | 5,784,000Source | 6,923,000Source | 2,094,000Source | -354,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 226,000Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,498,000Source | -15,557,000Source | -9,905,000Source | -10,561,000Source | -9,036,000Source | 56,542,000Source | 22,367,000Source | -69,676,000Source | -82,442,000Source | -91,169,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.15Source | -0.28Source | -0.17Source | -0.19Source | -0.16Source | 1Source | 0.39Source | -1.27Source | -1.88Source | -2.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.15Source | -0.28Source | -0.17Source | -0.19Source | -0.16Source | 0.98Source | 0.39Source | -1.27Source | -1.88Source | -2.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 56,929,103Source | 56,507,956Source | 57,367,283Source | 56,803,450Source | 57,233,413Source | 56,663,798Source | 56,868,111Source | 55,028,371Source | 43,954,649Source | 36,325,586Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 56,929,103Source | 56,507,956Source | 57,367,283Source | 56,803,450Source | 57,233,413Source | 57,673,099Source | 57,562,746Source | 55,028,371Source | 43,954,649Source | 36,325,586Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,541,000Source | 5,216,000Source | 4,664,000Source | 4,101,000Source | 4,256,000Source | 4,964,000Source | 16,572,000Source | 27,469,000Source | 27,110,000Source | 28,391,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | 22,365,000Source | -69,676,000Source | -82,442,000Source | -91,169,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 22,365,000Source | -69,676,000Source | -82,639,000Source | -91,270,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -2,250,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,480,000Source | 2,573,000Source | 2,152,000Source | 2,859,000Source | 2,223,000Source | 2,012,000Source | 9,845,000Source | 9,105,000Source | 4,018,000Source | 3,909,000Source |
| Operating ExpensesUSD | — | — | 10,978,000Source | 18,130,000Source | 12,057,000Source | 13,420,000Source | 11,259,000Source | 15,470,000Source | 57,478,000Source | 78,781,000Source | 86,460,000Source | 92,828,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 5,279,000Source | 5,275,000Source | 5,218,000Source | 5,342,000Source |
| Research and Development ExpenseUSD | — | — | 7,437,000Source | 12,914,000Source | 7,393,000Source | 9,319,000Source | 7,003,000Source | 10,506,000Source | 33,558,000Source | 51,312,000Source | 59,350,000Source | 64,437,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 70,000,000Source | 70,000,000Source | — | — | — |
Filing attachments
tm2615293d1_ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 tm2615293d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose dependent and manageable AE profile, no new safety signals obse…
Read attachment ↗tm2532577d1_ex99-1.htm · 8-K · 2025-12-03
EX-99.1 2 tm2532577d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to date PFS data for 1L NSCLC patients expected in Q2 202…
Read attachment ↗tm2532577d1_ex99-2.htm · 8-K · 2025-12-03
EX-99.2 3 tm2532577d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Developing MasterKey Therapies to Defeat Cancer Resistance December 3, 2025 2 Forward - Looking Statements This presentation contains forward looking statements of Black Diamond Therapeutics, Inc (“we,” “us,” “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be i…
Read attachment ↗tm259476d1_ex99-1.htm · 8-K · 2025-03-19
EX-99.1 2 tm259476d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small ce…
Read attachment ↗tm259476d1_ex99-2.htm · 8-K · 2025-03-19
EX-99.2 3 tm259476d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Developing MasterKey Therapies to Defeat Cancer Resistance March 19, 2025 2 Forward - Looking Statements This presentation contains forward looking statements of Black Diamond Therapeutics, Inc (“we,” “us,” “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be iden…
Read attachment ↗